Meeting
2022 ASCO Annual Meeting
Predominance of BRCA2 mutation and estrogen receptor-positive breast cancer among BRCA1/2 mutation carriers.
Authors
Pascal Pujol
CREEC, UMR IRD 224-CNRS 5290 Université Montpellier, Montpellier, France
Pascal Pujol , Kévin Yauy , Amandine Coffy , Nicolas Duforet-Frebourg , Sana Gabteni , Jean-Pierre Daurès , Frederique Madeleine Penault-Llorca , Laetitia Collet , Frédéric Thomas , Clare Turnbull , Virginie Galibert , Chloé Rideau , Benoit You , David Geneviève , Kevin S. Hughes , Nicolas Philippe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 551)
DOI
10.1200/JCO.2022.40.16_suppl.551
Abstract #
551
Poster Bd #
323
Abstract Disclosures
Similar Posters
First Author: Emmanouil S. Saloustros
Poster
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
First Author: Susan M. Dombrowski
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2021 ASCO Annual Meeting
Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).
First Author: Felipe Batalini